Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Amidotrizoate→

Amidotrizoate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
117-96-4
Molecular formula
C11H9I3N2O4
Molecular weight
613.91 g/mol
Drug class
Ionic iodinated radiographic contrast medium (diatrizoate)
Mechanism of action
The iodine atoms attenuate X-rays, producing radiographic contrast. The agent is not a therapeutic receptor ligand; its diagnostic effect depends on the distribution and concentration of the contrast medium in the imaged body compartment.
Indications / reported uses
  • Radiographic contrast for selected urographic, angiographic and gastrointestinal examinations depending on the specific amidotrizoate salt, concentration and route
  • Use is formulation- and route-specific; water-soluble diatrizoate oral/rectal solutions and injectable contrast products are not interchangeable

Sources: NLM MeSH — Diatrizoate · US DailyMed — Diatrizoate meglumine/sodium products · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Amidotrizoate Environmental Risk Assessment (ERA) (the Amidotrizoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.